How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

17,049 results for

CNS Infection

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. CNS Fungal Infections

CNS Fungal Infections Rotation Prep | NEJM Resident 360 Social Login Email Login Log in via Email Create Your Account We will not share your email with anyone. Password must be at least 8 characters. Show or Hide the password you are typing. Request to Join has invited you to join this group Your browser does not support video tags Welcome! NEJM Resident 360 helps you prepare for your next rotation quickly and efficiently, provides support for coping with the pressures of resident life

2014 Now@NEJM

42. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. (PubMed)

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. The prognosis for primary CNS lymphoma has improved with the use of high-dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a chimeric monoclonal antibody that targets the CD20 cell surface protein, has substantial activity in systemic CD20-positive diffuse large B-cell lymphoma, but its efficacy in primary CNS lymphoma is unknown and low (...) penetration of the large rituximab molecule through the blood-brain barrier could limit its effect. We aimed to investigate the addition of rituximab to a high-dose methotrexate-based chemotherapy regimen in patients with newly diagnosed primary CNS lymphoma.This intergroup, multicentre, open-label, randomised phase 3 study was done at 23 hospitals in the Netherlands, Australia, and New Zealand. Non-immunocompromised patients aged 18-70 years with newly diagnosed primary CNS lymphoma were randomly

2019 Lancet Oncology

43. Characteristics, Management and Outcome of DLBCL patients, presenting with simultaneous Systemic and CNS disease at Diagnosis - A retrospective multicenter study. (PubMed)

Characteristics, Management and Outcome of DLBCL patients, presenting with simultaneous Systemic and CNS disease at Diagnosis - A retrospective multicenter study. The incidence of systemic diffuse large B cell lymphoma (DLBCL) concurrently involving the central nervous system (CNS) at diagnosis, is very low and data regarding the clinical course of these patients are scarce. We investigated characteristics, efficacy of treatment regimens including consolidative autologous stem cell (...) transplantation and outcome of patients presenting with concomitant systemic and CNS DLBCL. The records of 44 patients, diagnosed between 2004 and 2017, who fulfilled the inclusion criteria, were retrospectively reviewed. CNS involvement was diagnosed as solely parenchymal in 41%, solely leptomeningeal in 43%, and paranchymal with leptomeningeal in 11% of the patients. Induction regimens were anthracycline-based combined with high-dose methotrexate (HD-MTX) in 80% (n = 35) of patients, anthracycline-based

2019 American journal of hematology

44. CNS small vessel disease: A clinical review. (PubMed)

CNS small vessel disease: A clinical review. CNS small vessel disease (CSVD) causes 25% of strokes and contributes to 45% of dementia cases. Prevalence increases with age, affecting about 5% of people aged 50 years to almost 100% of people older than 90 years. Known causes and risk factors include age, hypertension, branch atheromatous disease, cerebral amyloid angiopathy, radiation exposure, immune-mediated vasculitides, certain infections, and several genetic diseases. CSVD can

2019 Neurology

45. Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. (PubMed)

Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Although the CNS is immune privileged, continuous search for pathogens and tumours by immune cells within the CNS is indispensable. Thus, distinct immune-cell populations also cross the blood-brain barrier independently of inflammation/under homeostatic conditions. It was previously shown that effector memory T cells populate healthy CNS parenchyma in humans (...) and, independently, that CCR5-expressing lymphocytes as well as CCR5 ligands are enriched in the CNS of patients with multiple sclerosis. Apart from the recently described CD8+ CNS tissue-resident memory T cells, we identified a population of CD4+CCR5high effector memory cells as brain parenchyma-surveilling cells. These cells used their high levels of VLA-4 to arrest on scattered VCAM1, their open-conformation LFA-1 to crawl preferentially against the flow in search for sites permissive for extravasation

2019 Brain

46. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. (PubMed)

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. The PI3K/Akt/mTOR signaling pathway is aberrantly activated in various pediatric tumors. We conducted a phase I study of the Akt inhibitor perifosine in patients with recurrent/refractory pediatric CNS and solid tumors. This was a standard 3+3 open-label dose-escalation study to assess pharmacokinetics, describe toxicities, and identify the MTD for single-agent perifosine. Five dose levels (...) were investigated, ranging from 25 to 125 mg/m2/day for 28 days per cycle. Twenty-three patients (median age 10 years, range 4-18 years) with CNS tumors (DIPG [n = 3], high-grade glioma [n = 5], medulloblastoma [n = 2], ependymoma [n = 3]), neuroblastoma (n = 8), Wilms tumor (n = 1), and Ewing sarcoma (n = 1) were treated. Only one DLT occurred (grade 4 hyperuricemia at dose level 4). The most common grade 3 or 4 toxicity at least possibly related to perifosine was neutropenia (8.7

Full Text available with Trip Pro

2017 PLoS ONE

47. CNS infections in 2015: emerging catastrophic infections and new insights into neuroimmunological host damage (PubMed)

CNS infections in 2015: emerging catastrophic infections and new insights into neuroimmunological host damage 26700901 2016 04 27 2018 11 13 1474-4465 15 1 2016 Jan The Lancet. Neurology Lancet Neurol CNS infections in 2015: emerging catastrophic infections and new insights into neuroimmunological host damage. 17-9 10.1016/S1474-4422(15)00359-2 S1474-4422(15)00359-2 Williamson Peter R PR Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National (...) Institutes of Health, Bethesda, MD, USA. Nash Theodore E TE Laboratory of Parasitic Diseases, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20982, USA. Electronic address: tnash@niaid.nih.gov. Williamson Kim C KC Microbiology and Immunology Department, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. Nath Avindra A Section of Infections of the Nervous System, National Institute

Full Text available with Trip Pro

2015 The Lancet. Neurology

48. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal L (PubMed)

with ASCT than in those who received WBRT. Two toxic deaths (infections) were recorded, both in patients who received ASCT.WBRT and ASCT are both feasible and effective as consolidation therapies after high-dose methotrexate-based chemoimmunotherapy in patients aged 70 years or younger with primary CNS lymphoma. The risks and implications of cognitive impairment after WBRT should be considered at the time of therapeutic decision.Agenzia Italiana del Farmaco, Cancer Research UK, Oncosuisse, and Swiss (...) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal L The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results

2018 The Lancet. Haematology

49. Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Atezolizumab + Pertuzumab + Trastuzumab (...) In CNS Mets In BC The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03417544 Recruitment Status : Recruiting First Posted : January 31, 2018 Last Update Posted : February 22, 2018 See Sponsor: Nancy Lin, MD Collaborator

2018 Clinical Trials

50. Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Afatinib on CNS (...) to determine Central Nervous System (CNS) penetration of afatinib, as well as clinical activity. Patients will start on daily dosing initially followed by pulsed intermittent dosing should we observe no clinical activity. A secondary objective is to identify the resistance spectrum in leptomeningeal disease. It is anticipated that optimal dosing schedule of afatinib e.g. pulsed dosing may improve CNS disease control. Condition or disease Intervention/treatment Phase Non-small Cell Lung Cancer

2018 Clinical Trials

51. Evaluation of CN-105 in Subject With Acute Supratentorial Intracerebral Hemorrhage

[ Time Frame: 0-12 hour ] evaluate hematoma expansion Brain CT scan [ Time Frame: 48 Hour ] evaluate hematoma expansion Brain CT scan [ Time Frame: 96 hour ] evaluate hematoma expansion Brain CT scan [ Time Frame: 120 hour ] evaluate hematoma expansion Brain CT scan [ Time Frame: 24 hour ] evaluate hematoma expansion presence of CNS infection [ Time Frame: 24 hour ] meningitis, cerebritis, ventriculitis presence of CNS infection [ Time Frame: 72 hours ] meningitis, cerebritis, ventriculitis presence (...) of CNS infection [ Time Frame: 0-12 hour ] meningitis, cerebritis, ventriculitis presence of CNS infection [ Time Frame: 48 hours ] meningitis, cerebritis, ventriculitis presence of CNS infection [ Time Frame: 120 hour ] meningitis, cerebritis, ventriculitis presence of CNS infection [ Time Frame: 96 hour ] meningitis, cerebritis, ventriculitis presence of CNS infection [ Time Frame: 30 day ] meningitis, cerebritis, ventriculitis presence of CNS infection [ Time Frame: 90 day ] meningitis, cerebritis

2018 Clinical Trials

52. Concept Clearance » Novel Imaging Approaches for Detection of Persistent HIV in the CNS, HIV-Associated Inflammation, and Molecular Pathology

Rausch, Ph.D. Division of AIDS Research Purpose: The goal of this initiative is to encourage the use of current and novel imaging technologies to detect persistent, latent, and/or reactivated HIV, HIV viral products and associated pathology/inflammation in the central nervous system (CNS) in virally suppressed individuals on ART. Rationale: Mild to moderate CNS dysfunction continues to persist despite viral suppression in HIV-infected individuals on ART. The CNS is also considered a potential viral (...) /latent HIV infection of the CNS on both functional and structural neuronal connectivity specifically in the context of ART. Related Information Contact Us The National Institute of Mental Health Information Resource Center Available in English and Español Hours: 8:30 a.m. to 5 p.m. eastern time, M-F Phone: TTY: TTY (toll-free): Live Online Chat: Email: Fax: 1-301-443-4279 Mail: National Institute of Mental Health Office of Science Policy, Planning, and Communications 6001 Executive Boulevard, Room

2018 NIMH blog

53. Mass-spectrometric profiling of cerebrospinal fluid reveals metabolite biomarkers for CNS involvement in varicella zoster virus reactivation (PubMed)

Mass-spectrometric profiling of cerebrospinal fluid reveals metabolite biomarkers for CNS involvement in varicella zoster virus reactivation Varicella zoster virus (VZV) reactivation spans the spectrum from uncomplicated segmental herpes zoster to life-threatening disseminated CNS infection. Moreover, in the absence of a small animal model for this human pathogen, studies of pathogenesis at the organismal level depend on analysis of human biosamples. Changes in cerebrospinal fluid (CSF (...) ) metabolites may reflect critical aspects of host responses and end-organ damage in neuroinfection and neuroinflammation. We therefore applied a targeted metabolomics screen of CSF to three clinically distinct forms of VZV reactivation and infectious and non-infectious disease controls in order to identify biomarkers for CNS involvement in VZV reactivation.Metabolite profiles were determined by targeted liquid chromatography-mass spectrometry in CSF from patients with segmental zoster (shingles, n = 14

Full Text available with Trip Pro

2018 Journal of neuroinflammation

54. IFNγ inhibits G-CSF induced neutrophil expansion and invasion of the CNS to prevent viral encephalitis (PubMed)

IFNγ inhibits G-CSF induced neutrophil expansion and invasion of the CNS to prevent viral encephalitis Emergency hematopoiesis facilitates the rapid expansion of inflammatory immune cells in response to infections by pathogens, a process that must be carefully regulated to prevent potentially life threatening inflammatory responses. Here, we describe a novel regulatory role for the cytokine IFNγ that is critical for preventing fatal encephalitis after viral infection. HSV1 encephalitis (HSE (...) the opposing roles of G-CSF and IFNγ in regulation of innate inflammatory responses in a murine viral encephalitis model and reveals G-CSF as a potential therapeutic target. Thus, the antagonistic G-CSF-IFNγ interactions emerge as a key regulatory node in control of CNS inflammatory responses to virus infection.

Full Text available with Trip Pro

2018 PLoS pathogens

55. Human CNS Tau Kinetics in Tauopathies

Human CNS Tau Kinetics in Tauopathies Human CNS Tau Kinetics in Tauopathies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Human CNS Tau Kinetics in Tauopathies (TANGLES) The safety and scientific validity (...) Degeneration Tau Consortium Information provided by (Responsible Party): Washington University School of Medicine Study Details Study Description Go to Brief Summary: The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS and to test the hypothesis that tau kinetics are altered (i.e. increased production, decreased clearance, and increased aggregation rate) in tauopathies. Condition or disease Intervention/treatment Progressive Supranuclear Palsy (PSP) Corticobasal

2018 Clinical Trials

56. Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors

Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03598244 Recruitment Status : Suspended (Other - Company Review) First Posted : July 25, 2018 Last Update Posted : February 15, 2019 Sponsor: National Cancer

2018 Clinical Trials

57. HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

herniation Presence of active malignancy other than the primary CNS tumor under study Presence of active severe infection Receiving any anti-cancer agents or chemotherapy Pregnant or breastfeeding Subject and/or authorized legal representative unwilling or unable to provide consent/assent for participation in the 15-year follow up period Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol Contacts and Locations Go (...) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

58. [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma

[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03569995 Recruitment Status : Recruiting First Posted : June 26

2018 Clinical Trials

59. EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

and/or radiographic evidence of impending herniation Presence of active malignancy other than the primary CNS tumor under study Presence of active severe infection Receiving any anti-cancer agents or chemotherapy Pregnant or breastfeeding Subject and/or authorized legal representative unwilling to provide consent/assent for participation in the 15 year follow up period Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol (...) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2018 Clinical Trials

60. SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SGT-53 in Children With Recurrent or Progressive CNS Malignancies SGT-53 in Children With Recurrent or Progressive CNS Malignancies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. SGT-53 in Children (...) With Recurrent or Progressive CNS Malignancies The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03554707 Recruitment Status : Not yet recruiting First Posted : June 13, 2018 Last Update Posted : August 17, 2018 See Sponsor

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>